Consistency of Immunogenicity and Non Inferiority of Three Production Lots of GSK Biologicals' Candidate Malaria Vaccine in Children
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 327
- 试验地点
- 2
- 主要终点
- Anti-Circumsporozoite (Anti-CS) Antibody Titers
研究概览
简要总结
The purpose of this study is to show the consistency of different lots of a candidate vaccine (257049) against malaria developed by GlaxoSmithKline (GSK) Biologicals.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 5 Months 至 17 Months（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects who the investigator believes that their parent(s)/Legally Acceptable Representative(s) (LAR) can and will comply with the requirements of the protocol.
- •A male or female child between, and including, 5 and 17 months of age at the time of the first vaccination.
- •Signed or thumb-printed informed consent obtained from the parent(s)/LAR(s) of the child. Where parent(s)/LAR(s) are illiterate, the consent form will be countersigned by a witness.
- •Healthy subjects as established by medical history and clinical examination before entering into the study.
- •Subjects who have received three documented doses of hepatitis B vaccine.
排除标准
- •Same sex twins.
- •Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
- •Family history of congenital or hereditary immunodeficiency.
- •History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.
- •Major congenital defects or serious chronic illness.
- •History of any neurological disorders or seizures.
- •Moderate or severe malnutrition at screening defined as weight for age Z-score less than
- •Acute disease and/or fever at the time of enrolment
- •Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or medical history.
- •Use of a drug or vaccine that is not approved for that indication other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period.
- •Chronic administration of immunosuppressants or other immune-modifying drugs since birth.
- •Planned administration/administration of a licensed vaccine not foreseen by the study protocol within 7 days of the first dose of study vaccine.
- •Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
- •Administration of immunoglobulins and/or any blood products within 1 month preceding the first dose of study vaccine or planned administration during the study period.
- •Child in care.
- •Any other findings that the investigator feels would increase the risk of having an adverse outcome from participation in the trial.
研究组 & 干预措施
GSK 257049-Lot 1 Group
Healthy male or female children aged 5 to 17 months received 3 doses of the GSK 257049 vaccine from the commercial scale lot 1 (formulation 1 of the GSK 257049 vaccine) administered intramuscularly (IM) in the deltoid of the left arm, at Day 0, at Month 1 and at Month 2.
干预措施: GSK Biologicals' candidate Plasmodium falciparum malaria vaccine (257049) (Biological)
GSK 257049-Lot 2 Group
Healthy male or female children aged 5 to 17 months received 3 doses of the GSK 257049 vaccine, from the commercial scale lot 2 (formulation 2 of the GSK 257049 vaccine) administered intramuscularly (IM) in the deltoid of the left arm, at Day 0, at Month 1 and at Month 2.
干预措施: GSK Biologicals' candidate Plasmodium falciparum malaria vaccine (257049) (Biological)
GSK 257049-Lot 3 Group
Healthy male or female children aged 5 to 17 months received 3 doses of the GSK 257049 vaccine, from the commercial scale lot 3 (formulation 3 of the GSK 257049 vaccine) administered intramuscularly (IM) in the deltoid of the left arm, at Day 0, at Month 1 and at Month 2.
干预措施: GSK Biologicals' candidate Plasmodium falciparum malaria vaccine (257049) (Biological)
GSK 257049-Pilot Group
Healthy male or female children aged 5 to 17 received 3 doses of the GSK 257049 vaccine from the pilot scale (pilot formulation of the GSK 257049 vaccine) administered intramuscularly (IM) in the deltoid of the left arm, at Day 0, at Month 1 and at Month 2.
干预措施: GSK Biologicals' candidate Plasmodium falciparum malaria vaccine (257049) (Biological)
结局指标
主要结局
Anti-Circumsporozoite (Anti-CS) Antibody Titers
时间窗: One month post-dose 3 (Month 3)
Antibody titers are presented as geometric mean titers (GMTs) and are measured in titers.
次要结局
- Anti-hepatitis B (Anti-HB) Antibody Concentrations(One month post-dose 3 (Month 3))
- Number of Subjects With Unsolicited Adverse Events(Within the 30-day (Days 0-29) post-vaccination period)
- Number of Subjects With Any and Grade 3 Solicited Local Symptoms(Over a 7-day (Days 0-6)post-vaccination period after each dose and across doses)
- Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms(Over a 7-day (Days 0-6) post-vaccination period after each dose and across doses)
- Number of Subjects With Serious Adverse Events(Up to 8 months post-dose 1)